Loading...
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. BV has received accelerated approval from the US Food and Drug Admini...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3959807/ https://ncbi.nlm.nih.gov/pubmed/24672256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S57700 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|